Moleculin Biotech (MBRX) PT Set at $8.00 by Roth Capital

Moleculin Biotech (MBRX) PT Set at $8.00 by Roth Capital


The firm currently has a "buy" rating on the stock. Roth Capital's price target suggests a potential upside of 488.24% from the stock's previous close.



from Biotech News